Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 25;23(1):44.
doi: 10.1186/s12860-022-00440-7.

CLCA2 overexpression suppresses epithelial-to-mesenchymal transition in cervical cancer cells through inactivation of ERK/JNK/p38-MAPK signaling pathways

Wenhu Xin  1   2 , Jian Zhang  2 , Haibin Zhang  1 , Xueyao Ma  1 , Yunzhong Zhang  1 , Yufeng Li  1 , Fang Wang  3   4
Affiliations

CLCA2 overexpression suppresses epithelial-to-mesenchymal transition in cervical cancer cells through inactivation of ERK/JNK/p38-MAPK signaling pathways

Wenhu Xin et al. BMC Mol Cell Biol. .

Abstract

Cervical cancer is an important malignant tumor threatening the physical and mental health of women in the world. As a new calcium activated chloride channel protein, calcium activated chloride channel (CLCA2) plays an important role in tumorigenesis and development. But its role and exact regulatory mechanism in cervical cancer are still unclear. In our study, we found CLCA2 was significantly decreased in cervical cancer cells, and overexpression of CLCA2 inhibited the proliferation, migration and invasion, and promotes apoptosis of cervical cancer cells, and CLCA2 inhibited EMT (Epithelial-mesenchymal transition) through an p38 / JNK / ERK pathway. The results in vivo were consistent with those in vitro. In conclusion, overexpression of CLCA2 inhibited the progression of cervical cancer in vivo and in vitro. This may provide a theoretical basis for CLCA2 as a new indicator of clinical diagnosis and prognosis of cervical cancer or as a potential target of drug therapy.

Keywords: CLCA2; Cervical cancer; Progression; p38.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Decreased expression of CLCA2 in cervical cancer cells. A qRT-PCR results indicated that the expression of CLCA2 decreased in cervical cancer cells. B Westernblot results showed that the expression of CLCA2 decreased in cervical cancer cells. *P < 0.05, **P < 0.001, t-test
Fig. 2
Fig. 2
Overexpression of CLCA2 inhibits the proliferation, migration and invasion, and promotes apoptosis of cervical cancer cells. A qRT-PCR results indicated that the expression of CLCA2 increased after CLCA2 lentiviral plasmid transfection. B Overexpression of CLCA2 inhibited the proliferation of cervical cancer cells. C Overexpression of CLCA2 promoted apoptosis of cervical cancer cells. D Overexpression of CLCA2 inhibited the migration of cervical cancer cells. E Overexpression of CLCA2 inhibited the invasion of cervical cancer cells. *P < 0.05, **P < 0.001, t-test. N blank control, NC negative control. Scale bar = 25um
Fig. 3
Fig. 3
CLCA2 inhibits EMT and p38 / JNK / ERK pathway in cervical cancer cells. Overexpression of CLCA2 up-regulated the expression of E-cadherin and down-regulated the expression of N-cadherin, snail, and twist. A qRT-PCR; B Westernblot; C Immunofluorescence(400×). D Westernblot results showed CLCA2 inhibited the expression of p-p38, p-JNK, p-ERK, and the expression level of p38, JNK, and ERK remained unchanged. *P < 0.05, **P < 0.001, t-test. Scale bar = 25um
Fig. 4
Fig. 4
CLCA2 inhibits ocervical cancer growth and EMT in vivo. A, B CLCA2 overexpression led to a obvious reduction in tumor volume. C HE staining showed that the tumor cells had nuclear pyknosis and apoptosis. D TUNEL staining showed TUNEL positive cells were observed in tumors from CLCA2 overexpression treatment than those from NC treatment. E Immunofluorescence analysis of E-cadherin, N-cadherin, snail, twist and p-p38. F Westernblot analysis of E-cadherin, N-cadherin, snail, twist and p38. Scale bar = 100 μm, *P < 0.05, **P < 0.001, t-test. Scale bar = 25um
Fig. 5
Fig. 5
Schematic representation of the mechanism with antitumor effect of CLCA2
See this image and copyright information in PMC

References

    1. Buskwofie A, David-West G, Clare CA. A review of cervical Cancer: incidence and disparities [J] J Natl Med Assoc. 2020;112(2):229–232. - PubMed
    1. Wenzel HHB, Smolders RGV, Beltman JJ, et al. Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review [J] Eur J Cancer. 2020;133:14–21. doi: 10.1016/j.ejca.2020.04.006. - DOI - PubMed
    1. Zhen S, Lu J, Liu YH, et al. Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout [J] Cancer Gene Ther. 2020;27(3-4):168–178. doi: 10.1038/s41417-019-0131-9. - DOI - PubMed
    1. Jeon YH, Lee HW, Lee YL, et al. Combined E7-dendritic cell-based immunotherapy and human sodium/iodide symporter radioiodine gene therapy with monitoring of antitumor effects by bioluminescent imaging in a mouse model of uterine cervical cancer [J] Cancer Biother Radiopharm. 2011;26(6):671–679. doi: 10.1089/cbr.2011.1081. - DOI - PubMed
    1. Xiao J, Zhou J, Liang L, et al. Sensitivity of ASPP and P-gp to neoadjuvant chemotherapy combined with gene therapy in locally advanced cervical cancer [J] J BUON. 2019;24(3):967–974. - PubMed